Business Description
Newbury Pharmaceuticals AB
ISIN : SE0015244884
Compare
Compare
Traded in other countries / regions
NEWBRY.SwedenP52.Germany IPO Date
2022-02-04Description
Newbury Pharmaceuticals AB is a hybrid pharmaceutical company for specialty prescription drugs, innovation and brands with focus on the Scandinavian markets.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | 0.57 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 1.46 | |||||
| Beneish M-Score | -0.59 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 103.5 | |||||
| 3-Year EBITDA Growth Rate | -16.9 | |||||
| 3-Year EPS without NRI Growth Rate | -21.4 | |||||
| 3-Year FCF Growth Rate | 14.1 | |||||
| 3-Year Book Growth Rate | -4.5 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 70 | |||||
| 9-Day RSI | 60.17 | |||||
| 14-Day RSI | 55.17 | |||||
| 6-1 Month Momentum % | -4.05 | |||||
| 12-1 Month Momentum % | 2.47 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.49 | |||||
| Quick Ratio | 1.32 | |||||
| Cash Ratio | 0.52 | |||||
| Days Inventory | 88.83 | |||||
| Days Sales Outstanding | 120.73 | |||||
| Days Payable | 54.57 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -15.7 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 43.53 | |||||
| Operating Margin % | -38.23 | |||||
| Net Margin % | -41.83 | |||||
| FCF Margin % | -64.37 | |||||
| ROE % | -32.39 | |||||
| ROA % | -17.8 | |||||
| ROIC % | -19.11 | |||||
| ROCE % | -22.68 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 2.21 | |||||
| PB Ratio | 1.72 | |||||
| Price-to-Tangible-Book | 17.52 | |||||
| EV-to-EBIT | -5.25 | |||||
| EV-to-EBITDA | -5.99 | |||||
| EV-to-Revenue | 2.01 | |||||
| EV-to-FCF | -3.12 | |||||
| Price-to-Net-Current-Asset-Value | 17.52 | |||||
| Earnings Yield (Greenblatt) % | -19.05 | |||||
| FCF Yield % | -26.56 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Newbury Pharmaceuticals AB Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil kr) | 36.829 | ||
| EPS (TTM) (kr) | -0.753 | ||
| Beta | 0 | ||
| Volatility % | 76.14 | ||
| 14-Day RSI | 55.17 | ||
| 14-Day ATR (kr) | 0.152086 | ||
| 20-Day SMA (kr) | 3.5 | ||
| 12-1 Month Momentum % | 2.47 | ||
| 52-Week Range (kr) | 2.4 - 6.24 | ||
| Shares Outstanding (Mil) | 24.26 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Newbury Pharmaceuticals AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Newbury Pharmaceuticals AB Stock Events
| Event | Date | Price(kr) | ||
|---|---|---|---|---|
| No Event Data | ||||
Newbury Pharmaceuticals AB Frequently Asked Questions
What is Newbury Pharmaceuticals AB(OSTO:NEWBRY)'s stock price today?
The current price of OSTO:NEWBRY is kr3.68. The 52 week high of OSTO:NEWBRY is kr6.24 and 52 week low is kr2.40.
When is next earnings date of Newbury Pharmaceuticals AB(OSTO:NEWBRY)?
The next earnings date of Newbury Pharmaceuticals AB(OSTO:NEWBRY) is 2025-01-15.
Does Newbury Pharmaceuticals AB(OSTO:NEWBRY) pay dividends? If so, how much?
Newbury Pharmaceuticals AB(OSTO:NEWBRY) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers